Russia's most bloodthirsty serial killersWorld March 27, 17:36
UK foreign secretary postpones visit to MoscowWorld March 27, 17:33
Putin to discuss steps to improve living standards in Arctic at international forumBusiness & Economy March 27, 17:18
Israeli minister lauds coordination with Russia on SyriaWorld March 27, 16:57
Putin to visit Franz Josef Land to inspect ecological situation in Russia’s ArcticBusiness & Economy March 27, 16:26
FIDE president denies media reports on his resignationRussian Politics & Diplomacy March 27, 16:05
Russian opposition figure Navalny arrested for 15 days for resisting policeRussian Politics & Diplomacy March 27, 15:32
Duma Speaker points out Russian banks in Ukraine raided with EU’s ‘tacit consent’Business & Economy March 27, 15:21
Opposition figure Navalny fined $350 for unauthorized rally in downtown MoscowRussian Politics & Diplomacy March 27, 14:36
TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd. announced on April 16 that the abstract of phase 2a clinical study data of an oral alpha 4 integrin antagonist, development code AJM300, has been accepted for presentation at the Digestive Disease Week 2014 (May 3 - 6 in Chicago, USA). The contents of data will be presented at the beginning of Joint Presidential Plenary Session collaborated by the American Society for Gastrointestinal Endoscopy and the American Gastroenterological Association.
- Study data to be presented (Presentation date / time: USA Eastern time zone)
Abstract No.: 370
Title: AJM300, an Oral alpha 4 Integrin Antagonist, for Active Ulcerative Colitis: a Multicenter, Randomized, Double-Blind, Placebo- Controlled* Phase 2A Study
Presentation date / time: May 4, 2014, 1:36-1:46 PM, Oral presentation
*Randomized double-blind, placebo-controlled study
Randomized double-blind, placebo-controlled study is a method of study to objectively evaluate the efficacy of medicine. In the study, neither investigators nor patients know which the patient takes a placebo (a mimic preparation that looks like a study drug but contains no active ingredient) or the study drug.
About Ajinomoto Pharmaceuticals Co., Ltd.
Representative Director,President & CEO: Takashi Nagamachi
Headquarters, Chuo-ku, Tokyo
Hajime Ito, Corporate Planning Dept, Ajinomoto Pharmaceuticals Co., Ltd.